About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT02735447

Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study

Sporadic inclusion body myositis (sIBM) is a rare idiopathic inflammatory myopathy characterized by chronic proximal leg and distal arm asymmetric muscle weakness. Its prevalence is estimated between ...

Lead sponsor: La-ser Europe Limited•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Clémentine Nordon, MD, PhD

CONTACT

+33 (0) 1 83 62 91 53 Clementine.Nordon@la-ser.com

Sponsors

Lead Sponsor

La-ser Europe Limited

Age

45 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The patient has been diagnosed with sIBM, as per the physician judgement and regardless of the date of diagnosis
•Male or female
•Age ≥ 45 years old
•The patient does regularly live in the country of inclusion
•The patient or his/her proxy can read and respond to a telephone interview
•The patient agrees to participate

Exclusion Criteria

•The patient refuses to participate or the written Consent Form is not signed
•The patient or his/her proxy cannot be reached by telephone.

Related studies

RECRUITINGEARLY Phase 1

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies

COMPLETEDPhase 1

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

NCT04421677 · Inclusion Body Myositis, Sporadic Inclusion Body Myositis

COMPLETEDPhase 2

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT01423110 · Sporadic Inclusion Body Myositis

COMPLETEDPhase 3

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467 · Sporadic Inclusion Body Myositis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 18, 2016Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment190

Start dateMay 2016

Last updatedApr 18, 2016

Condition

Sporadic Inclusion Body Myositis

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 18, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions